Christopher A. Viehbacher

Chris has over 25 years of experience in the biotech and pharmaceutical industries. He is the former CEO and Member of the Board of Directors of Sanofi, a Fortune 50 Biopharmaceutical company based in Paris with sales of over $35 billion and a market capitalization of over $100 billion. During Chris’s six year tenure Sanofi underwent a significant business transformation, completed over $30 billion of acquisitions, most notably that of Genzyme, and developed a novel approach to building a pipeline of new medicines. Chris was also the Chairman of the Board of Genzyme in Boston.

In 2015 Chris joined the Board of Directors of Pure Tech as well as the Board of Vedanta, a Pure Tech portfolio company. He also joined the Board of Trustees of Northeastern University. Prior to joining Sanofi, Chris spent 20 years with GlaxoSmithKline in Germany, Canada, France and, ultimately, the US as President of GSK’s North American pharmaceutical division. Chris was a Member of the Board of Directors of GSK plc in London and Co-President of GSK’s Portfolio Management Board. Chris began his career with Price Waterhouse after graduating with a degree in Commerce at Queen’s University in Canada. Chris qualified as a Chartered Accountant while with Price Waterhouse in Canada and later with PW in Hamburg, Germany.